EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC 4.0

A Randomized Phase 1 Study Comparing the PK , PD , Safety, and Immunogenicity of Proposed Biosimilar RGB ‐14‐X and Denosumab in Healthy Adult Males

Emmanuel Biver iD, Jean-Jacques Body iD, Ashwin Sachdeva iD, Hana Študentová iD, Zsuzsanna Nagy iD, Attila Kun iD, Károly Horvát-Karajz iD, Joachim Kiefer iD, Tímea Pap iD, Enikő Jókai iD, Ferenc Béla Vasas, Lothar Seefried iD

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70468 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Emmanuel Biver und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Bone Diseases, Department of Medicine, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Switzerland. Hauptthemen laut MEDLINE: Denosumab, Biosimilar Pharmaceuticals, Bone Density Conservation Agents. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Denosumab is a monoclonal antibody targeting the receptor activator of nuclear factor kappa‐b ligand widely used for the prevention of skeletal‐related events in patients with bone metastases. This Phase 1 randomized, double‐blind, two‐arm, parallel‐group study assessed the equivalence in pharmacokinetics (PK) and compared the pharmacodynamics (PD), safety, and immunogenicity of the proposed biosimilar RGB‐14‐X and reference denosumab in healthy males. Participants were randomized 1:1 to a single subcutaneous 60 mg dose of RGB‐14‐X or reference denosumab, with 252 days of follow‐up. Primary PK endpoints were maximum observed serum concentration (C max ) and area under the concentration‐time curve from time 0 to last quantifiable concentration (AUC 0‐last ) and extrapolated to infinity (AUC 0‐inf ). Secondary objectives were to compare additional PK parameters, safety and tolerability, PD and immunogenicity between groups. Of 165 participants randomized, 162 (98.2%) completed the study. The geometric mean ratios and corresponding 90% confidence intervals of RGB‐14‐X versus reference denosumab for C max , AUC 0‐last , and AUC 0‐inf were within the pre‐specified range of 0.80–1.25, demonstrating equivalence. No notable differences were observed in secondary PK or PD parameters between groups; maximum reduction in concentration of the bone resorption marker serum C‐terminal telopeptide of type I collagen (CTX) and the extent and duration of reduction in CTX levels over time were similar. RGB‐14‐X was well tolerated with a similar safety profile to reference denosumab. No anti‐drug or neutralizing antibodies were detected in either group. RGB‐14‐X demonstrated biosimilarity to reference denosumab, with equivalent PK and similar PD, safety, and immunogenicity outcomes in healthy males.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DenosumabBiosimilar PharmaceuticalsBone Density Conservation AgentsHumansMaleAdultDouble-Blind MethodMiddle AgedHealthy VolunteersTherapeutic EquivalencyYoung AdultArea Under CurveInjections, SubcutaneousCollagen Type IPeptides

Stichwörter der Autor:innen

adverse eventsbioequivalencehealthy subjectsmonoclonal antibodiespharmacodynamicspharmacokinetics‐pharmacodynamics

Substanzen

DenosumabBiosimilar PharmaceuticalsBone Density Conservation AgentsCollagen Type Icollagen type I trimeric cross-linked peptidePeptides

Autor:innen und Institutionen

  • Division of Bone Diseases, Department of Medicine, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Switzerland.
  • Department of Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
  • Division of Cancer Sciences, University of Manchester, Manchester, UK.
  • Department of Oncology, Palacký University, Faculty of Medicine and Dentistry, University Hospital, Olomouc, Czech Republic.
  • Gedeon Richter Plc, Hungary.
  • Musculoskeletal Center Würzburg, University of Würzburg, Würzburg, Germany.

ORCID-Profile: Emmanuel Biver, Jean-Jacques Body, Ashwin Sachdeva, Hana Študentová, Zsuzsanna Nagy, Attila Kun, Károly Horvát-Karajz, Joachim Kiefer, Tímea Pap, Enikő Jókai, Lothar Seefried

Zitieren

APA

Biver, E., Body, J. J., Sachdeva, A., Študentová, H., Nagy, Z., Kun, A., Horvát-Karajz, K., Kiefer, J., Pap, T., Jókai, E., Vasas, F. B., & Seefried, L. (2026). A Randomized Phase 1 Study Comparing the PK , PD , Safety, and Immunogenicity of Proposed Biosimilar RGB ‐14‐X and Denosumab in Healthy Adult Males. Clinical and Translational Science. https://doi.org/10.1111/cts.70468

Vancouver

Biver E, Body JJ, Sachdeva A, Študentová H, Nagy Z, Kun A, et al. A Randomized Phase 1 Study Comparing the PK , PD , Safety, and Immunogenicity of Proposed Biosimilar RGB ‐14‐X and Denosumab in Healthy Adult Males. Clinical and Translational Science. 2026. doi:10.1111/cts.70468

BibTeX
@article{Biver2026,
  author = {Biver, Emmanuel and Body, Jean-Jacques and Sachdeva, Ashwin and Študentová, Hana and Nagy, Zsuzsanna and Kun, Attila and Horvát-Karajz, Károly and Kiefer, Joachim and Pap, Tímea and Jókai, Enikő and Vasas, Ferenc Béla and Seefried, Lothar},
  title = {A Randomized Phase 1 Study Comparing the PK , PD , Safety, and Immunogenicity of Proposed Biosimilar RGB ‐14‐X and Denosumab in Healthy Adult Males},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70468}
}
Kostenlos starten →